Vinicius Lima Faustino

Vinicius Lima Faustino

Auto-generated profile, based on publicly available information

Vinicius Lima Faustino

Global Medical & Scientific Affairs (GMSA), MSD Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Interface - Comunicação, Saúde, Educação
Verified
Journal Article
Open access
VFVinicius Lima Faustino
Vinicius Lima Faustino
GSGiulia Brambillo dos Santos
Giulia Brambillo dos Santos
PAPatricia Melo Aguiar
Patricia Melo Aguiar
A educação centrada no estudante, como principal responsável na construção do seu próprio conhecimento, é extremamente importante para que as metodologias de ensino tradicionais cada vez mais sejam substituídas por metodologias ativas de ensino-aprendizagem. Trata-se de relato de experiência entre monitores e docente da disciplina de Política de Saúde e Gestão da Assistência Farmacêutica do curso de Farmácia da Faculdade de Ciências Farmacêuticas da Universidade de São Paulo (USP), com o objetivo de relatar a experiência no desenvolvimento de jogos educativos como estratégia na construção do conhecimento na área da Assistência Farmacêutica. A gamificação se mostrou uma estratégia pedagógica aplicável ao ensino remoto e em turmas com grande quantidade de estudantes, sendo capaz de motivar e facilitar o aprendizado, tornando esse processo mais prazeroso e estimulando os estudantes de Farmácia a superarem os seus próprios resultados de aprendizagem.

6 March 2024 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
VFVinicius Lima Faustino
Vinicius Lima Faustino
MVMarília Berlofa Visacri
Marília Berlofa Visacri
PAPatricia Melo Aguiar
Patricia Melo Aguiar

12 December 2024 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
ABAmanda Azevedo Bittencourt
Amanda Azevedo Bittencourt
VFVinicius Lima Faustino
Vinicius Lima Faustino
PBPaula Batista
Paula Batista
LLLays Paulino Leonel
Lays Paulino Leonel
MPMarina Della Negra de Paula
Marina Della Negra de Paula
TPThales José Polis
Thales José Polis
Increased spread of antimicrobial resistance by Gram-Negative Bacilli (GNB) poses a global challenge, with exacerbated burden post-pandemic. The aim of this study was to investigate the in vitro activity of ceftolozane/tazobactam and its comparators against the frequently identified GNB isolated from patients admitted to Brazilian medical sites between the year 2018‒2019 and 2020‒2021. The impact of pandemic on antimicrobial resistance and presence of β-lactamase genes were also evaluated. Antimicrobial susceptibility testing and molecular characterization of ß-lactamase encoding genes using Polymerase Chain Reaction (PCR) and DNA sequencing were carried out from GNB isolated mostly from intra-abdominal, respiratory, and urinary tract infections and interpreted following BrCAST/EUCAST guidelines. A total of 3994 GNB isolates were evaluated which mostly included E. coli, K. pneumoniae and P. aeruginosa. Ceftolozane/tazobactam remained highly active against E. coli isolates during both 2018‒2019 (96.0 %) and 2020‒2021 (98.5 %). Among K. pneumoniae, ceftolozane/tazobactam (47.6 % and 43.0 % susceptible during 2018‒2019 and 2020‒2021, respectively) showed poor activity due to blaKPC-2. Colistin and ceftolozane/tazobactam were the most active β-lactam agents tested against P. aeruginosa in 2018‒2019 (99.3 % and 88.8 %) and 2020‒2021 (100 % and 92.8 %), including ceftazidime and meropenem resistant isolates. β-lactamase encoding gene characterization was carried out and both carbapenemases and Extended-Spectrum β-Lactamase (ESBL) producers were found in E. coli, K. pneumoniae and P. aeruginosa isolates. Ceftolozane/tazobactam documented remarkable in vitro activity against E. coli and P. aeruginosa isolates in Brazil, both pre- and post-pandemic periods and could constitute an effective therapeutic option for the treatment of urinary tract infections, intra-abdominal infections, and respiratory tract infections.

1 July 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
ABAmanda Azevedo Bittencourt
Amanda Azevedo Bittencourt
VFVinicius Lima Faustino
Vinicius Lima Faustino
PBPaula de Mendonça Batista
Paula de Mendonça Batista
LLLays Paulino Leonel
Lays Paulino Leonel
MPMarina Della Negra de Paula
Marina Della Negra de Paula
TPThales José Polis
Thales José Polis
The Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program tested imipenem/relebactam (IMR) and comparators against a total of 2,258 non-duplicate clinical isolates of Enterobacterales (Klebsiella pneumoniae and Escherichia coli ) collected across six Brazilian cities during 2020–2021. Antimicrobial susceptibility was determined by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpreted following Brazilian Committee on Antimicrobial Susceptibility (BrCAST)/European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. Enterobacterales isolates were screened for β-lactamase genes ( bla ) by sequencing. The most frequent isolates identified among Enterobacterales were E. coli ( n = 471; 20.9%) and K. pneumoniae ( n = 453; 20.1%). Susceptibility testing showed that >99% of E. coli isolates were susceptible to colistin ([COL], n = 470; 99.8%), meropenem ([MEM], n = 468; 99.4%), IMR ( n = 468; 99.4%), and ceftazidime/avibactam ([CZA], n = 468; 99.4%), whereas a high proportion of E. coli multidrug-resistant (MDR) isolates were susceptible to COL ( n = 69; 98.6%), CZA ( n = 67; 95.7%), MEM ( n = 67; 95.7%), IMR ( n = 67; 95.7%), and amikacin ([AMK], n = 66; 94.3%). Overall, K. pneumoniae isolates were most susceptible to CZA ( n = 414; 91.4%) and IMR ( n = 411; 90.7%) and over 86.0% of K. pneumoniae MDR isolates were susceptible to CZA ( n = 268; 87.3%) and IMR ( n = 265; 86.3%). This study reported that IMR was one of the most effective in vitro β-lactam–β-lactamase inhibitor combinations tested and demonstrated comparable activity to CZA and higher activity than COL against both the Enterobacterales species tested. IMPORTANCE: As new mechanisms of antibiotic resistance continue to emerge, especially with the rise of carbapenem resistance, this study emphasizes the importance of assessing the current landscape of antimicrobial resistance to identify optimal therapeutic approaches. In this way, the publication of national data is significant for understanding local epidemiology to evaluate new drugs and make the best choice among the antimicrobials available in the hospital environment, both for critically ill patients with resistant bacterial infections.